148 related articles for article (PubMed ID: 1370328)
1. Re: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation).
Fosså JD; Dearnaley DP
J Urol; 1992 Jan; 147(1):173-4. PubMed ID: 1370328
[No Abstract] [Full Text] [Related]
2. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation).
Morgan WR; Zincke H; Rainwater LM; Myers RP; Klee GG
J Urol; 1991 Feb; 145(2):319-23. PubMed ID: 1703241
[TBL] [Abstract][Full Text] [Related]
3. The value of prostate-specific antigen in the management of localized prostatic cancer.
Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation.
Wiegel T; Hinkelbein W
Front Radiat Ther Oncol; 2002; 36():35-42. PubMed ID: 11842753
[No Abstract] [Full Text] [Related]
5. Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Nativ O; Myers RP; Farrow GM; Therneau TM; Zincke H; Lieber MM
J Urol; 1990 Aug; 144(2 Pt 1):303-6. PubMed ID: 1695690
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy.
Link P; Freiha FS; Stamey TA
J Urol; 1991 Mar; 145(3):532-4. PubMed ID: 1705294
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy.
Hudson MA; Catalona WJ
J Urol; 1990 Jun; 143(6):1174-7. PubMed ID: 1692887
[TBL] [Abstract][Full Text] [Related]
8. The value of serum prostate specific antigen determinations before and after radical prostatectomy.
Lange PH; Ercole CJ; Lightner DJ; Fraley EE; Vessella R
J Urol; 1989 Apr; 141(4):873-9. PubMed ID: 2467013
[TBL] [Abstract][Full Text] [Related]
9. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels.
Lange PH; Lightner DJ; Medini E; Reddy PK; Vessella RL
J Urol; 1990 Oct; 144(4):927-32; discussion 932-3. PubMed ID: 1697918
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
11. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
12. [Adenocarcinoma of the prostate: pathological stage C. 2: Treatment].
Flam T; Zerbib M; Steg A; Debré B
J Urol (Paris); 1991; 97(7-8):305-8. PubMed ID: 1811022
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC
J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037
[TBL] [Abstract][Full Text] [Related]
14. Controversies in management of apparently localized carcinoma of prostate.
Lange PH
Urology; 1989 Oct; 34(4 Suppl):13-8; discussion 46-56. PubMed ID: 2477933
[TBL] [Abstract][Full Text] [Related]
15. Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: intermediate findings.
Freeman JA; Lieskovsky G; Cook DW; Petrovich Z; Chen S; Groshen S; Skinner DG
J Urol; 1993 May; 149(5):1029-34. PubMed ID: 8483203
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the prostate involving 2 cell types (prostate specific antigen producing and carcinoembryonic antigen producing) with selective metastatic spread.
Guthman DA; Farrow GM; Myers RP; Ferrigni RG; Lieber MM
J Urol; 1991 Sep; 146(3):854-6. PubMed ID: 1714970
[TBL] [Abstract][Full Text] [Related]
17. Artificial prostate-specific antigen persistence after radical prostatectomy.
Poyet C; Hof D; Sulser T; Müntener M
J Clin Oncol; 2012 Feb; 30(5):e62-3. PubMed ID: 22203757
[No Abstract] [Full Text] [Related]
18. Evaluation of a new tumor marker for localized prostate cancer.
Culkin DJ; Gelder FB; Vick SR; Parra BL; Mata JA; Venable DD; Zitman RA
Prostate; 1992; 20(2):117-22. PubMed ID: 1372428
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
20. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
